Global Market for Hospital Infection Therapeutics to Register 3.10% CAGR from 2014 to 2020 due to Increasing Number of Pipeline Drug Molecules
Albany, NY -- (SBWIRE) -- 12/11/2017 -- As per the research study, in 2013, the global market for hospital infection therapeutics was valued at US$3.1 bn and is estimated to reach US$3.6 bn by the end of 2020. The market is predicted to exhibit a 3.10% CAGR between 2014 and 2020.
The Global Hospital Infection Therapeutics Market is segmented on the basis of Drug Type, Major Infections, Geography.
Based on the major prominent types of drugs in the market, the global market for hospital infection therapeutics has been segmented into antiviral, antibacterial, and antifungal drugs. In 2013, the antibacterial drugs segment dominated the market, accounting for a 70.7% share in the global market for hospital infection therapeutics. This segment is projected to grow at a fast pace in the next few years. The research study has further analyzed the major drugs in the pipeline, including Plazomicin, Ceftolozane, Delafloxacin, Eravacycline, Surotomycin, Tedizolid, Amikacin Inhale, MK-3415A, CAZ AVI, Dalvance, and Oritavancin.
Read Report Overview @ https://www.transparencymarketresearch.com/hospital-infection-therapeutics.html
On the basis of type of infection, the global market for hospital infection therapeutics has been categorized into gastrointestinal disorders, hospital-acquired pneumonia, urinary tract infections, surgical site infections, bloodstream infections, and other infections. In 2013, the hospital-acquired pneumonia segment accounted for a 20% share in the global market for hospital infection therapeutics. Nevertheless, the urinary tract infections segment is anticipated to grow rapidly in the near future.
Currently, North America leads the overall market and is estimated to remain in the leading position in the next few years. North America is closely trailed by Europe. The rapid growth of these two regional markets can be attributed to the increasing healthcare awareness and growing demand for advanced drugs. On the other hand, the Asia Pacific market for hospital infection therapeutics is estimated to witness the fastest growth throughout the forecast period.
Request Sample Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1280
Summary of Table of Content
2. Executive Summary
3. Hospital Infection Therapeutics Market Overview
4. Hospital Infection Therapeutics Market, by Drug Type
5. Hospital Infection Therapeutics Market, by Major Infections
6. Hospital infection therapeutics Market, by Geography
8. Company Profiles
Request to Browse Full Table of Content, figure and Tables @ https://www.transparencymarketresearch.com/report-toc/1280